New pill plus chemo shows early promise in tough pancreatic cancer

NCT ID NCT05586516

Completed Disease control Sponsor: iOnctura Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested an experimental oral drug called IOA-289 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in 16 people with metastatic pancreatic cancer. The main goal was to check safety and find the right dose. Researchers also looked at how the drug behaves in the body and any signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IOA-289 (an experimental oral drug) combined with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to: If it works, this could point toward a new treatment option for metastatic pancreatic cancer by adding an oral drug to standard chemotherapy.
What could go wrong: This is a very early, small trial (16 people) focused on safety and dosing, not yet on effectiveness. The drug may not work or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fibrosis malignant pancreatic neoplasm neoplasm Neoplasm Metastasis pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC CANCER

Contacts and locations

Locations

Beatson West of Scotland Cancer Center

Glasgow, G12 0YN, United Kingdom
Medical Oncology and Immunotherapy Unit, University Hospital of Siena

Siena, 53100, Italy
UO Oncologia of Azienda Ospedaliera Universitaria Integrata di Verona

Verona, Verona, 37126, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.